Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population


Por: Magnano, L, Alonso-Alvarez, S, Alcoceba, M, Rivas-Delgado, A, Muntanola, A, Nadeu, F, Setoain, X, Rodriguez, S, Andrade-Campos, M, Espinosa-Lara, N, Rodriguez, G, Sancho, JM, Moreno, M, Mercadal, S, Carro, I, Salar, A, Garcia-Pallarols, F, Arranz, R, Cannata, J, Terol, MJ, Teruel, AI, Jimenez-Ubiet, A, Rodrigue, A, de Villambrosi, SG, Bell, JL, Lopez, L, Novelli, S, de Cabo, E, Infante, ME, Pardal, E, Monsalvo, S, Gonzalez, M, Martin, A, Caballero, MD, Lopez-Guillermo, A

Publicada: 1 may 2019
Resumen:
The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their status at 30 months from the start of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). The training series comprised 263 patients consecutively diagnosed with FL in a 10-year period who needed therapy and were treated with rituximab-containing regimens. An independent cohort of 693 FL patients from the Grupo Espanol de Linfomas y Trasplante Autologo de Medula & Oacute; sea (GELTAMO) group was used for validation. In the training cohort, 188 patients were in CR30, with a 10-year overall survival (OS) of 53% and 87% for non-CR30 and CR30 patients, respectively. Ten-year RS was 73% and 100%, showing no decrease in life expectancy for CR30 patients. Multivariate analysis indicated that the FL International Prognostic Index was the most important variable predicting OS in the CR30 group. The impact of CR30 status on RS was validated in the independent GELTAMO series. In conclusion, FL patients treated with immunochemotherapy who were in CR at 30 months showed similar survival to a sex- and age-matched Spanish general population.

Filiaciones:
Magnano, L:
 Hosp Clin Barcelona, Haematol Dept, Villarroel 170, E-08036 Barcelona, Spain

 CIBERONC, Madrid, Spain

Alonso-Alvarez, S:
 Hosp Univ Salamanca, Haematol Dept, Salamanca, Spain

 IBSAL, Salamanca, Spain

Alcoceba, M:
 CIBERONC, Madrid, Spain

 Hosp Univ Salamanca, Haematol Dept, Salamanca, Spain

 IBSAL, Salamanca, Spain

Rivas-Delgado, A:
 Hosp Clin Barcelona, Haematol Dept, Villarroel 170, E-08036 Barcelona, Spain

 CIBERONC, Madrid, Spain

Muntanola, A:
 Hosp Univ Mutua Terrassa, Haematol Dept, Terrassa, Spain

Nadeu, F:
 Inst Invest Biomed August Pi & Sunyer IDIBAP, Lymphoid Neoplasms Program, Barcelona, Spain

Setoain, X:
 CIBER BBN 2, Hosp Clin Barcelona, Nucl Med Dept, Barcelona, Spain

Rodriguez, S:
 CIBER BBN 2, Hosp Clin Barcelona, Nucl Med Dept, Barcelona, Spain

Andrade-Campos, M:
 Hosp Miguel Servet, Haematol Dept, Zaragoza, Spain

Espinosa-Lara, N:
 Hosp Miguel Servet, Haematol Dept, Zaragoza, Spain

Rodriguez, G:
 Hosp Virgen Rocio, Haematol Dept, Seville, Spain

Sancho, JM:
 Hosp GermansTrias & Pujol ICO IJC, Haematol Dept, Badalona, Spain

Moreno, M:
 Hosp GermansTrias & Pujol ICO IJC, Haematol Dept, Badalona, Spain

Mercadal, S:
 Hosp Duran & Reynals ICO, Haematol Dept, Hospitalet, Barcelona, Spain

Carro, I:
 Hosp Duran & Reynals ICO, Haematol Dept, Hospitalet, Barcelona, Spain

Salar, A:
 Hosp Mar, Haematol Dept, Barcelona, Spain

Garcia-Pallarols, F:
 Hosp Mar, Haematol Dept, Barcelona, Spain

Arranz, R:
 Hosp Princesa, Haematol Dept, Madrid, Spain

Cannata, J:
 Hosp Princesa, Haematol Dept, Madrid, Spain

Terol, MJ:
 Hosp Clin Valencia, Haematol Dept, Valencia, Spain

Teruel, AI:
 Hosp Clin Valencia, Haematol Dept, Valencia, Spain

Jimenez-Ubiet, A:
 Hosp 12 Octubre, Haematol Dept, Madrid, Spain

Rodrigue, A:
 Hosp 12 Octubre, Haematol Dept, Madrid, Spain

de Villambrosi, SG:
 Hosp Valdecilla Santander, Haematol Dept, Santander, Spain

Bell, JL:
 Hosp Nuestra Senora Esperanza, Haematol Dept, Santiago De Compostela, Spain

Lopez, L:
 Hosp MD Anderson, Haematol Dept, Madrid, Spain

Novelli, S:
 Hosp Santa Creu & Sant Pau, Haematol Dept, Barcelona, Spain

de Cabo, E:
 Hosp Bierzo, Haematol Dept, Ponferrada, Spain

Infante, ME:
 Hosp Infanta Leonor, Haematol Dept, Madrid, Spain

Pardal, E:
 Hosp Virgen Puerto, Haematol Dept, Plasencia, Spain

Monsalvo, S:
 Hosp Fdn Jimenez Diaz, Haematol Dept, Madrid, Spain

Gonzalez, M:
 CIBERONC, Madrid, Spain

 Hosp Univ Salamanca, Haematol Dept, Salamanca, Spain

 IBSAL, Salamanca, Spain

Martin, A:
 CIBERONC, Madrid, Spain

 Hosp Univ Salamanca, Haematol Dept, Salamanca, Spain

 IBSAL, Salamanca, Spain

Caballero, MD:
 CIBERONC, Madrid, Spain

 Hosp Univ Salamanca, Haematol Dept, Salamanca, Spain

 IBSAL, Salamanca, Spain

Lopez-Guillermo, A:
 Hosp Clin Barcelona, Haematol Dept, Villarroel 170, E-08036 Barcelona, Spain

 CIBERONC, Madrid, Spain
ISSN: 00071048





BRITISH JOURNAL OF HAEMATOLOGY
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 185 Número: 3
Páginas: 480-491
WOS Id: 000465109900010
ID de PubMed: 30793290
imagen Bronze

MÉTRICAS